The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.
Altrius Global Dividend ETF (DIVD)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
33.68 unch (unch) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 33.68 unch (unch) 16:15 ET
for Fri, Apr 25th, 2025